

STATEMENT OF MEDICAL NECESSITY

The **Oncoguard™ Liver** test is a convenient single blood test that combines analysis of methylated DNA markers and the biomarker alpha fetoprotein with a sophisticated algorithm to help identify hepatocellular carcinoma (HCC) in at-risk patients.

Patient Name: _____ **Patient Date of Birth:** _____

Insurance Payer Name: _____ **Insurance ID:** _____

Ordering Physician Name: _____ **Ordering Physician NPI:** _____

Office Address: _____

Office Phone: _____ **Office Fax:** _____

CPT Code: 81599

Date of Specimen Collection: _____ (MM/DD/YYYY)

ICD-10 Code(s): _____

Symptoms/Clinical Findings:

- Cirrhosis of the liver Hepatitis B infection (HBV) Fatty liver disease
 Other _____ Other _____ Other _____

Prior History (check all the apply):

- Hepatitis B infection (HBV) Hepatitis C infection (HCV) Alcohol
 Non-alcoholic fatty liver disease (NAFLD) Genetic disorders: _____

Authorized Signature: _____ **Date:** _____

Routine surveillance plays an important role in diagnosing HCC in its early stages and is recommended in AASLD and NCCN guidelines. This diagnosis is indicative of the patient being at-risk for HCC. To confirm the need for a diagnostic follow-up for potential HCC, it is imperative to perform the Oncoguard Liver test.

AASLD¹

Population:	Cirrhosis and/or HBV (selected)
Surveillance Method(s):	Ultrasound +/- AFP
Frequency:	Every 6 months

1. Heimbach JK, et al. *Hepatology*. 2018;67(1):358-380. AASLD—American Association for the Study of Liver Diseases